LYRIQ Trademark

Trademark Overview


On Thursday, July 17, 2025, a trademark application was filed for LYRIQ with the United States Patent and Trademark Office. The USPTO has given the LYRIQ trademark a serial number of 99288539. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Wednesday, August 13, 2025. This trademark is owned by Globus Medical, Inc.. The LYRIQ trademark is filed in the Medical Instrument Products category with the following description:

Surgical implants comprising artificial material and associated surgical instrument sets
lyriq

General Information


Serial Number99288539
Word MarkLYRIQ
Filing DateThursday, July 17, 2025
Status653 - SUSPENSION LETTER - MAILED
Status DateWednesday, August 13, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesSurgical implants comprising artificial material and associated surgical instrument sets

Classification Information


International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateThursday, July 17, 2025
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGlobus Medical, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAudubon, PA 19403

Trademark Events


Event DateEvent Description
Thursday, July 17, 2025NEW APPLICATION ENTERED
Thursday, July 17, 2025APPLICATION FILING RECEIPT MAILED
Thursday, July 17, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 8, 2025ASSIGNED TO EXAMINER
Wednesday, August 13, 2025SUSPENSION LETTER WRITTEN
Wednesday, August 13, 2025LETTER OF SUSPENSION E-MAILED
Wednesday, August 13, 2025NOTIFICATION OF LETTER OF SUSPENSION E-MAILED